Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: A RECORD-1 subgroup analysis Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Immunosuppressive Agents
  • Kidney Neoplasms
  • Protein Kinase Inhibitors
  • Receptors, Vascular Endothelial Growth Factor
  • Salvage Therapy
  • Sirolimus

abstract

  • Everolimus is well tolerated and efficacious with no increased toxicity in patients intolerant to VEGFr-TKI therapy.

publication date

  • April 24, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3341863

Digital Object Identifier (DOI)

  • 10.1038/bjc.2012.89

PubMed ID

  • 22441644

Additional Document Info

start page

  • 1475

end page

  • 80

volume

  • 106

number

  • 9